Matt Chrysler
About Matt Chrysler
Matt Chrysler: Head of Portfolio & Alliance Management at TRexBio
Matt Chrysler is the Head of Portfolio & Alliance Management at TRexBio, a role he has held since joining the company in 2019. With over 15 years of experience in portfolio and commercial management across both emerging and well-established biotechnology firms, Matt brings a wealth of knowledge and expertise to TRexBio. His tenure at TRexBio is marked by driving innovations and strategic alliances that empower the company's growth within the biotechnological landscape.
Matt Chrysler's Previous Role at Ultragenyx
Before joining TRexBio, Matt Chrysler most recently held the position of Head of New Product Planning at Ultragenyx. In this capacity, he led early-stage pipeline strategy decisions for potential gene therapy, biologic, and small molecule therapeutics. His strategic insights and leadership were crucial in shaping the direction of Ultragenyx's product pipeline, contributing to the company's long-term growth and advancement in the biotechnology sector.
Matt Chrysler: Global Commercial Lead at Ultragenyx
In his earlier role at Ultragenyx, Matt Chrysler served as the Global Commercial Lead for multiple late-stage programs. He was instrumental in overseeing launch preparations for Crysvita, coordinating efforts with a global pharmaceutical partner. His role in these high-stake launches highlights his capability in managing complex commercial strategies and collaborations at an international scale.
Matt Chrysler's Early Career: Genentech and ZS Associates
Matt Chrysler's career began at ZS Associates as a Management Consultant, where he honed his analytical and consulting skills. Later, he transitioned to Genentech, where he worked in various roles encompassing portfolio management, corporate strategy, and brand management. These roles provided Matt with a robust foundation in biotechnology management and set the stage for his subsequent positions in the industry.
Matt Chrysler: Educational Background
Matt Chrysler holds an MBA and an MS in biochemistry from Georgetown University, complementing his BS in microbiology from the University of Washington. His advanced education in both business and scientific disciplines equips him with a unique blend of skills essential for managing and strategizing within the biotechnology sector.